Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 4, 2002, Pages 347-356

  Ritsner, Michael ^a   Kurs, Rena ^a  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

Author keywords

Adverse events; Atypical antipsychotic agents; Objective quality of life; Schizophrenia; Subjective quality of life; Typical antipsychotic agents

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE;

ANTICHOLINERGIC EFFECT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MEDLINE; ORTHOSTATIC HYPOTENSION; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036048585     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.4.347     Document Type: Review

References (78)

1. Antipsychotic drug treatment: Recent advances
2. Iatrogenic disorders associated with conventional vs. atypical antipsychotics
3. Critical analysis and comparison of the side effect and safety profiles of the new antipsychotics
4. The psychopharmacology of schizophrenia
5. An overview of side effects caused by typical antipsychotics
6. Atypical antipsychotic agents: A critical review
7. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
8. The economic impact of schizophrenia
9. Antipsychotic medication adherence: Is there a difference between typical and atypical agents
10. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
11. Economic outcomes of antipsychotic agents in a Medicaid population: Traditional agents vs. risperidone
12. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting
13. Atypical antipsychotics: Part II: Adverse effects, drug interactions and costs
14. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center
15. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: A cost-utility analysis
16. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
17. Health-related quality-of-life assessment and planning for the pharmaceutical industry
18. Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome
19. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
20. Some adverse effects of antipsychotics: Prevention and treatment
21. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors
22. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
23. Real progress - The patient's perspective
24. Relatively small impact adverse events of antipsychotics on life satisfaction of schizophrenia patients: A naturalistic study
25. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients
26. The use of the Liverpool University Neuroleptic Side effect Rating Scale (LUNSERS) in clinical practice
27. Distress scale for adverse symptoms: A new instrument for measuring the relationship between adverse drug symptoms and associated distress
28. Differences in Quality of Life Domains, Psychopathological and Psychosocial Factors in Psychiatric Patients
29. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)
30. Measuring quality of life: Methodological issues
31. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes
32. The World Health Organization Quality of Life Assessment (WHOQOL): Position paper from the World Health Organization
33. Measures of quality of life among persons with severe and persistent mental disorders
34. Quality of life in first-admitted schizophrenia patients: A follow-up study
35. Quality of life of schizophrenic patients on medications and implications for new drug trials
36. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation
37. Measuring the quality of life of clients with severe mental illness: A review of instruments
38. Measuring quality of life in patients with schizophrenia
39. Refining quality of life: Validating a multidimensional factor measure in the severe mentally ill
40. Assessing the quality of life in mental illness
41. Measuring the value of program outcomes: A review of multiattribute utility measures
42. Subject and observer-rated quality of life in schizophrenia
43. Subjective and objective dimensions of quality of life in psychiatric patients: A factor analytical approach: The South Verona Outcome Project 4
44. The Quality of Life Scale: An instrument for rating the schizophrenic deficit scale
45. Detecting improvement in quality of life and symptomatology in schizophrenia
46. How useful is the concept of quality of life in psychiatry?
47. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life
48. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure
49. Subjective quality of life in severely mentally ill patients: A comparison of two instruments
50. Chronic mental patients: The quality of life issue
51. Measuring quality of life in a reformed health system
52. Quality of Life and Mental Health Service
53. The well-being of chronic mental patients: Assessing their quality of life
54. Characterizing quality of life among patients with chronic mental illness: A critical examination of the self-report methodology
55. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
56. Convergent validation of quality of life assessments for persons with severe mental illnesses
57. Quality of life in schizophrenia: A comparison of instruments
58. Differences in health values among patients, family members and providers of outcome in schizophrenia
59. Psychosocial outcomes in patients with schizophrenia: Quality of life and reintegration
60. Quality of life in treated and never-treated schizophrenic patients
61. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
62. Does participation in psychosocial treatment augment the benefit of clozapine?
63. Quality of Life in Schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic out-patients undergoing risperidone maintenance treatment
64. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
65. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial
66. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
67. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample
68. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
69. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia
70. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
71. Social functioning and quality of life in the schizophrenic patient: Advantages of amisulpride
72. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride
73. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life
74. Influence of novel and conventional antipsychotic medication on subjective quality of life
75. Quality of life in schizophrenia: Insight and subjective response to neuroleptics
76. Subjective experience and mental side effects of antipsychotic treatment
77. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
78. Quality of life and treatment costs in schizophrenic out-patients, treated with depot neuroleptics